Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Lancet
    March 2025
  1. BONACA MP, Catarig AM, Houlind K, Ludvik B, et al
    Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00509-4. doi: 10.1016/S0140-6736(25)00509.
    >> Share

  2. DENNIS JM, Young KG, Cardoso P, Gudemann LM, et al
    A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
    Lancet. 2025;405:701-714.
    >> Share

  3. SEIDU S, Ikhile D
    Personalised type 2 diabetes therapy in primary care.
    Lancet. 2025;405:672-674.
    >> Share

    January 2025
  4. ADLER AI, Coleman RL, Whiteley WN, Holman RR, et al
    The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
    Lancet. 2025;405:29.
    >> Share

  5. HOU R, Ren J
    The legacy effect of hyperglycaemia in type 2 diabetes.
    Lancet. 2025;405:28-29.
    >> Share

  6. PRATTICHIZZO F, Ceriello A
    The legacy effect of hyperglycaemia in type 2 diabetes.
    Lancet. 2025;405:28.
    >> Share

    November 2024

  7. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants.
    Lancet. 2024;404:2077-93.
    >> Share

  8. GUARIGUATA L, Sobers N
    Rising diabetes, lagging treatment, and the need for better systems.
    Lancet. 2024 Nov 12:S0140-6736(24)02422-X. doi: 10.1016/S0140-6736(24)02422.
    >> Share

    September 2024
  9. LOVE KM, Brown SA
    The promise of once-weekly insulins for type 1 diabetes: update on progress.
    Lancet. 2024;404:1081-1083.
    >> Share

  10. BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
    Lancet. 2024;404:1132-1142.
    >> Share

    August 2024
  11. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    >> Share

  12. DELLGREN JL, Persad G, Emanuel EJ
    International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.
    Lancet. 2024 Aug 16:S0140-6736(24)01356-4. doi: 10.1016/S0140-6736(24)01356.
    >> Share

  13. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    >> Share

    July 2024
  14. RODRIGUEZ-GUTIERREZ R
    Legacy effect of intensive glycaemic control in type 2 diabetes-the UKPDS.
    Lancet. 2024;404:100-102.
    >> Share

  15. SIMMONS D, Gupta Y, Hernandez TL, Levitt N, et al
    Call to action for a life course approach.
    Lancet. 2024;404:193-214.
    >> Share

    June 2024
  16. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    >> Share

  17. STRASSBURGER MATZENBACHER L, Alessi J, Telo GH
    Diabetes management amidst floods in Brazil.
    Lancet. 2024 Jun 26:S0140-6736(24)01177-2. doi: 10.1016/S0140-6736(24)01177.
    >> Share

  18. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    >> Share

  19. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    >> Share

    May 2024
  20. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    >> Share

  21. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    >> Share

  22. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    >> Share

  23. ADLER AI, Coleman RL, Leal J, Whiteley WN, et al
    Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Lancet. 2024 May 17:S0140-6736(24)00537-3. doi: 10.1016/S0140-6736(24)00537.
    >> Share

    March 2024
  24. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    >> Share

  25. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016